← Back to Clinical Trials
Recruiting NCT07176936

NCT07176936 Improving Speech in Noise Using Noninvasive Stimulation

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT07176936
Status Recruiting
Phase
Sponsor University of Florida
Condition Traumatic Brain Injury
Study Type INTERVENTIONAL
Enrollment 55 participants
Start Date 2026-03-21
Primary Completion 2027-07-31

Eligibility & Interventions

Sex All sexes
Min Age 25 Years
Max Age 55 Years
Study Type INTERVENTIONAL
Interventions
Cymba Conchae stimulationEarlobe stimulation

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 55 participants in total. It began in 2026-03-21 with a primary completion date of 2027-07-31.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

Traumatic brain injury, a common injury in military service personnel, often leads to poor processing of speech in noisy environments. The goal of the current study is to better understand the brain basis for this difficulty and evaluate a new approach to improving speech in noise perception.

Eligibility Criteria

Inclusion Criteria: * 25-55 years old * Proficiency in English * TBI group: history of traumatic brain injury by blast or physical trauma * Normal hearing group: no history of traumatic brain injury Exclusion Criteria: * Other neurological diseases or related conditions will be excluded (e.g., large vessel stroke, seizures). We will exclude patients with severe medical diseases that may be associated with impaired cognition (e.g., heart failure, dialysis dependent kidney disease, brain cancer). Further, psychiatric diseases that are unlikely to be related to trauma will be excluded (e.g., schizophrenia). Patients with histories of severe psychiatric disease prior to trauma exposure will be excluded. * Current illicit or prescription drug abuse (within the last two months) * Any taVNS contraindication, including but not limited to the presence of unremovable metal in the left ear, known heart conditions, medications that influence neurotransmitters thought to be critical for vagus nerve stimulation (norepinephrine, acetylcholine, and serotonin), or implanted medical devices such as a pacemaker.

Frequently Asked Questions

Who can join the NCT07176936 clinical trial?

This trial is open to participants of all sexes, aged 25 Years or older, up to 55 Years, studying Traumatic Brain Injury. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT07176936 currently recruiting?

Yes, NCT07176936 is actively recruiting participants. Visit ClinicalTrials.gov or contact University of Florida to inquire about joining.

Where is the NCT07176936 trial being conducted?

This trial is being conducted at Gainesville, United States.

Who is sponsoring the NCT07176936 clinical trial?

NCT07176936 is sponsored by University of Florida. The trial plans to enroll 55 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: July 2026  ·  Data Methodology